My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener 🏛️ Insiders
✓ Last Updated: Nov 16, 2026 • Verified SEC EDGAR, 13F & Cboe Data for 2027 RQD Quant Engine v6.2 Live

West Pharmaceutical Services Inc. (WST) — RQD Stock Rating Cockpit

$396.64 -1.83% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $396.29

West Pharmaceutical Services Inc. (WST) earns a Roarable Rating of B+ (Buy) with 76/100 RQD Confidence. High-quality cash engine (35.9% gross margin, 18% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B+ • BUY Cap $27.63B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on WST Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is WST stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-22, West Pharmaceutical Services Inc. (NYSE: WST) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 76/100 at a spot price of $396.64 (-1.83% 1D, market cap $27.63B). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 14/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 15/20, and Executive Insider Alignment 11/20. Across 1015 tracked Health Care issuers, WST ranks #17 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does WST compare to DXCM and RMD in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), WST carries a Roarable B+ (76/100 RQD), trailing P/E of 59.4x, gross margin of 35.9%, and ROIC of 17.9%. By comparison, DXCM (DexCom Inc.) holds a B grade (75/100 RQD, P/E 36.1x, ROIC 21.6%, cap $29.91B) and RMD (ResMed Inc.) posts a A- grade (81/100 RQD, P/E 25.4x, ROIC 22.9%, cap $33.32B). Among the 5-stock peer group, SOLV leads on earnings multiple (9.1x) while RMD leads on capital efficiency (22.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for WST?
▼

Per WST's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000105770), West Pharmaceutical Services Inc. generated $3.07B in revenue (+6.3% YoY), $493.7M in net income, and $468.9M in free cash flow against $4.27B in total assets and $202.8M in total debt. Key quantitative strengths: Strong cash generator (35.9% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Priced at 59x earnings—high expectations leave less room for a lukewarm quarter. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
🎯 WST TRADE EXECUTION LEVELS + TODAY'S TOP 3 TRADES EXACT ENTRY • HARD STOP-LOSS (SUP) • TARGET (RES) • WHY

Where to Enter $WST, Where to Set Your Hard Stop-Loss & Today's Top 3 High-Conviction Trades

🏆 RECENT ALERT WINNERS: $XYZ +15.6% (2d) $PLTR +13.7% (4d) $VRT +8.4% (2d)
CURRENT TICKER SETUP • $WST R/R 3.6 : 1 • RQD 76/100 (B+)
$WST
Spot $396.64
1. GET IN (ENTRY)
$394.26–$398.62
2. HARD STOP (SUP)
$380.38 (-4.1%)
3. GET OUT (T1/T2)
$431.54 / $455.34
STOP-LOSS FLOOR (SUP $380.38): Hard stop sits 4.1% below spot to cap downside below key institutional support. If $WST closes a daily candle below $380.38, step aside.
PROFIT TARGETS (RES $431.54 / $455.34): Scale out 50% at T1 (+8.8%) and trail stop to breakeven for T2 (+14.8%).
Want this $WST sheet + Today's Top 3 Trades emailed free? Paper Trade $WST →
⚡ TODAY'S TOP 3 SUGGESTED TRADES OF THE DAY (100% FREE CHEAT SHEET) Trade #1 Unlocked • Enter Email Below to Unblur #2 & #3 + Get $WST Sheet
#1 • $ANET R/R 2.6 : 1
Arista Networks Inc.
IN
$164.14
STOP
$154.80
OUT
$178.00
#2 • 🔒 LOCKED R/R 2.6 : 1
AI Liquid-Cooling Leader
Target: +8.81% to +15.06% | Stop: -5.73%
#3 • 🔒 LOCKED R/R 2.3 : 1
Cash-Flow Buyback Machine
Target: +6.22% to +10.48% | Stop: -4.52%
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $396.28 (-0.09%)🧬 Disciplined Float (+0.24% YoY Shares)⚙️ Cash Engine: 18/20 (A) • 15.3% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 76/100 (B+) historically ranked in the Top 11% of excess returns over the next 90 days (+7.6% avg 90D alpha vs SPY • 70.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERBUY • B+
025507510076
3-of-3 Quant Analysts Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw B · Rk A-
Cash (18)Whales (14)SEC (18)Macro (15)CEO (11)
Each axis scored 0–20
12M PRICE TARGET CONE+8.1% Base Target
$506 Bull$429 Base$325 Bear
📬 FREE WST RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for WST)Realized 20D OHLCV Swing Band: ±3.8%
Deterministic 5-Pillar Attribution (76/100 Composite)
🔍 WHY WST SCORES 76/100 (B+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+18/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 15.3% FCF Margin ($468.9M FCF) & 35.9% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (24% of score)

Altman Z-Score 19.06 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 9/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution11/20 pts (-9 pt drag)

Disciplined Float (+0.24% YoY Shares) & executive Form 4 sales trim 9 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
68
Grade B-$393.23+4.9% Next Q
Q2 (-2Q)
71
Grade B$412.64+1% Next Q
Q3 (-1Q)
73
Grade B$416.60-4.8% Next Q
Current
76
Grade B+$396.64+7.6% Hist 90D α
Trajectory: B- (68) → B+ (76)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the WST Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 76/100 (B+) score, WST faces multiple-compression risk if 59.4x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Priced at 59x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (+0.24% YoY Shares) — any gross margin slip below 33.4% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($391.27) or 200D SMA ($329.75) invalidates the momentum regime and cuts Target Base ($428.77) toward Bear Floor ($325.24).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $WST• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “WST Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
RSI-14 MOMENTUMNEUTRAL RANGE
44.630 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
19.06>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
9 / 99-Pt Accounting
52-WEEK LASER RANGE81% OF RANGE
L: $224$396.64H: $438
1. Money & Cash Health● HEALTHY
Are profits real cash in the bank?

Real cash coming in backs up reported profits (35.9% gross margin and healthy balance-sheet cushion).

Factor Grade: ARQD 18 / 20
2. Big Money & Insiders● NEUTRAL
Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: CRQD 25 / 40
3. Hidden Risks & Market Weather● ALL CLEAR
SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: A-RQD 33 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

3-of-3 Quant Analysts Bullish on WST

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BULLISH (90)

17.9% ROIC with 35.9% gross margin and 1.60% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (90)

Altman-Z 19.06 and Piotroski 9/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BULLISH (67)

25/40 institutional & smart-money positioning score with 15/20 macro alignment.

Bull Case: Why Buyers Like WST
  • ✓Strong cash generator (35.9% gross margin)—profits are backed by real money, not accounting tricks.
  • ✓Clean SEC annual filing review with no major hidden accounting time-bombs.
Bear Case: What Could Go Wrong
  • !Priced at 59x earnings—high expectations leave less room for a lukewarm quarter.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (WST Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
WST // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +25.45%▲ ASCENDING CHANNEL
2026-11-22O $404.0H $404.0L $396.6C $396.6VOL 819.6K
$450.4$400.2$349.9$299.7$249.4RES $454.2SUP $343.8$396.62026-05-262026-07-132026-08-272026-10-132026-11-22
🏛️ GURU-GRADE VALUATION & FORENSIC ACCOUNTING ENGINE WIDE ECONOMIC MOAT (ROIC 17.9% vs WACC 8.9%)

WST Intrinsic Fair Value Line, Peter Lynch Corridor, Forensic Trio & Warning Signs

1-SECOND VISUAL VALUATION ANCHOR (COMPOSITE DCF + PETER LYNCH + GRAHAM)
Fair Value: $211.44 vs Spot $396.64
MODESTLY OVERVALUED (-87.6%)
Undervalued Zone (< $180) Fair Value Corridor ($180–$243) Overvalued (> $243)
$397
⚡ INTERACTIVE 10-YEAR DCF SANDBOX

Test Your Own WST Growth & WACC Assumptions

YOUR DCF TARGET
$259.73
5-Yr Annual FCF Growth Rate: 12.5%
Discount Rate (WACC Hurdle): 8.9%
Year-10 Terminal FCF Multiple: 16.0x
Margin of Safety: -87.6% vs $396.64 Full DCF Table →
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

WST Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
41.2%/yr Implied 5Y Growth

vs. +6.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on WST today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →
WST → LLY Confirmed Filing
West Pharmaceutical Services manufactures NovaPure fluoropolymer-coated elastomer plungers and cartridge seals required inside sterile single-dose and multi-dose GLP-1 auto-injector pens.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for WST today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (WST)

Health Care Rank #17 of 1015 ⚔️ DXCM vs WST Full Matrix →

1. Head-to-Head Health Care Peer Comparison (WST vs. DXCM, RMD, MDLN, SOLV)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, West Pharmaceutical Services Inc. (WST) ranks #17 by composite RQD confidence (76/100, grade B+) and #62 by equity capitalization ($27.63B). Within this direct 5-issuer industry benchmark cohort, SOLV leads on earnings valuation at 9.1x trailing P/E, while RMD leads on capital efficiency and profitability with 22.9% ROIC and 59.4% gross margin. RMD currently holds the highest overall quantitative score in the immediate peer group at 81/100 (A-) compared with WST at 76/100 (B+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
WST ACTIVE
West Pharmaceutical Services Inc.
B+ 76/100 59.4x 35.9% 17.9% -1.83% $27.63B Benchmark Subject
DXCM
DexCom Inc.
B 75/100 36.1x 60.1% 21.6% -2.82% $29.91B /dxcm-vs-wst →
RMD
ResMed Inc.
A- 81/100 25.4x 59.4% 22.9% -2.35% $33.32B /rmd-vs-wst →
MDLN
Medline Inc.
D 48/100 — — 8.2% -3.37% $49.77B /mdln-vs-wst →
SOLV
Solventum Corporation
D 45/100 9.1x 53.5% 18.7% -0.82% $14.56B /solv-vs-wst →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000105770 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), West Pharmaceutical Services Inc. (WST) reported GAAP revenue of $3.07B (+6.3% vs. FY2024 revenue of $2.89B , and +4.2% cumulative change since FY2023) , GAAP net income of $493.7M, operating cash flow of $754.8M, and free cash flow of $468.9M (+69.6% YoY). On the balance sheet, WST closed FY2025 with $4.27B in total assets against $202.8M in total debt (Altman Z-Score: 19.06, Piotroski F-Score: 9/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $3.07B $493.7M $754.8M $468.9M $4.27B $202.8M
FY2024 (FY) 2024-12-31 $2.89B $492.7M $653.4M $276.4M $3.64B $202.6M
FY2023 (FY) 2023-12-31 $2.95B $593.4M $776.5M $643.8M $16.13B $3.77B

3. WST Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is WST stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-22, West Pharmaceutical Services Inc. (NYSE: WST) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 76/100 at a spot price of $396.64 (-1.83% 1D, market cap $27.63B). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 14/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 15/20, and Executive Insider Alignment 11/20. Across 1015 tracked Health Care issuers, WST ranks #17 in composite RQD confidence.

How does WST compare to DXCM and RMD in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), WST carries a Roarable B+ (76/100 RQD), trailing P/E of 59.4x, gross margin of 35.9%, and ROIC of 17.9%. By comparison, DXCM (DexCom Inc.) holds a B grade (75/100 RQD, P/E 36.1x, ROIC 21.6%, cap $29.91B) and RMD (ResMed Inc.) posts a A- grade (81/100 RQD, P/E 25.4x, ROIC 22.9%, cap $33.32B). Among the 5-stock peer group, SOLV leads on earnings multiple (9.1x) while RMD leads on capital efficiency (22.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for WST?

Per WST's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000105770), West Pharmaceutical Services Inc. generated $3.07B in revenue (+6.3% YoY), $493.7M in net income, and $468.9M in free cash flow against $4.27B in total assets and $202.8M in total debt. Key quantitative strengths: Strong cash generator (35.9% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Priced at 59x earnings—high expectations leave less room for a lukewarm quarter. Institutional options positioning shows a 50% call / 50% put premium split.

Where is WST trading relative to its 50-day, 200-day, and 52-week technical levels?

WST last traded at $396.64 (-1.83% on volume of 819,624 shares), positioning the stock +1.37% above its 50-day simple moving average ($391.27) and +20.29% above its 200-day simple moving average ($329.75). Across its 52-week range of $223.83 to $438.27, WST sits at the 80.6% percentile with a 14-day RSI of 44.6 (NEUTRAL RANGE) and an implied next-earnings move of ±3.8% ($381.57 to $411.71).

ROARABLE RATING BRIEF • RQD 76/100 (B+) ✓ SEC XBRL & RQD VERIFIED

WST — West Pharmaceutical Services Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

West Pharmaceutical Services Inc. (WST) earns a live Roarable RQD composite score of 76/100, corresponding to a B+ letter grade (Roarable Buy) at a spot price of $396.64 (-1.83% 1D, market capitalization $27.63B).

  • Fundamental Cash Engine (18/20): Anchored by return on invested capital (ROIC) of 17.9%, gross margin of 35.9%, operating margin of 19.0%, and free cash flow yield of 1.60%.
  • Whale 13F & Options Flow (14/20) + Insider Conviction (11/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (15/20) + Forensic Balance Sheet (18/20): Incorporates a 1.08x equity beta, Altman Z-Score of 19.06, Piotroski F-Score of 9/9, and Debt/Equity of 0.06x.

2. Business Model, Unit Margins & SEC Financial Trajectory

. Is a NYSE-listed issuer in the Health Care sector, Medical/Dental Instruments industry. The company manufactures NovaPure fluoropolymer-coated elastomer plungers and cartridge seals used inside sterile GLP-1 auto-injector pens, positioning it as a component supplier to biopharma drug delivery. — for customer concentration, segment revenue split, or detailed revenue model.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), West Pharmaceutical Services Inc. (WST) reported $3.07B in annual revenue (up from $2.89B in FY2024, +6.3% YoY) and $493.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($2.95B revenue, $593.4M net income) through FY2025, WST scaled operating cash flow to $754.8M and free cash flow to $468.9M, backed by $4.27B in total assets against $202.8M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (B+ • RQD 76/100): Strong cash generator (35.9% gross margin)—profits are backed by real money, not accounting tricks. Clean SEC annual filing review with no major hidden accounting time-bombs. With Fundamental Cash Engine at 18/20 and Institutional Whale Flow at 14/20, sustained execution supports upside toward the upper end of the $223.83 – $438.27 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Priced at 59x earnings—high expectations leave less room for a lukewarm quarter. Investors must weigh 59.4x trailing P/E and 34.7x EV/EBITDA against 19.0% operating margins and a 1.08x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream/downstream: per the graph, WST sits upstream of Eli Lilly (LLY) as a direct supplier. Exposure is described only as "Undisclosed %," so the dependency size cannot be quantified.

Bottlenecks to watch, per the graph:

  • High-Value Product cleanroom molding capacity expansion in Dublin/Waterford.
  • Destocking of inventory by non-GLP-1 pharma customers, creating mixed short-term utilization.

Competing explanation, per the graph: successful commercialization of small-molecule oral GLP-1 pills (e.g., Lilly orforglipron) could reduce long-term per-patient growth in sterile injectable elastomer demand. This is a second-order risk to the tailwind thesis.

  • Key Question #1: Can WST sustain or expand its 19.0% operating margin and 17.9% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $3.07B and free cash flow of $468.9M, how will capital allocation balance growth reinvestment against $202.8M in total debt?
  • Key Question #3: How sensitive is WST's 55.2x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.08x)?

WST Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for West Pharmaceutical Services Inc. (WST) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to WST Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

WST Bull vs. Bear Conversation Board — What's Your Call at $396.64?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON WST 🐻 33% BEARISH CONVICTION
1. Pick Your Side on WST:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $528.15 (+28.0%)
📌 Pinned Debate

Per the RQD rating, 17.9% ROIC, a Piotroski F-Score of 9/9, and Debt/Equity of 0.06 point to a high-return, low-leverage business.

Picked up a starter position in WST in my $100K Virtual Cash book at $412.62. Per the RQD rating, 17.9% ROIC, a Piotroski F-Score of 9/9, and Debt/Equity of 0.06 point to a high-return, low-leverage business.. Trading inside a $223.83–$438.27 52-week range with 1.6% FCF yield gives solid downside support if Medical/Dental Instruments multiples expand this quarter.

RetailWhale_TX 🐂 BULL

Both sides have a point here — WST's 18/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $350.73 (-15.0%)
Spot @ $412.62

Per the market data, a P/E (TTM) of 59.4 and an FCF yield of 1.6% leave little valuation cushion if cash generation disappoints.

Here is the bear case nobody on the bull side wants to address on WST: Per the market data, a P/E (TTM) of 59.4 and an FCF yield of 1.6% leave little valuation cushion if cash generation disappoints.. At 59.4x trailing P/E, even a small guidance miss in Medical/Dental Instruments triggers a 12-15% air pocket.

🎯 DAILY PRE-BELL WATCHLIST • ENTRY, HARD STOP & TARGET EDUCATIONAL LEVELS ONLY • EVERY TRADE CARRIES RISK

3 Stocks on Our Radar Today — Entry, Hard Stop & Why

📊 Recent Paper Examples (Not Typical Real-Money Results): $XYZ +15.6% (2d) $PLTR +13.7% (4d) $VRT +8.4% (2d)
TRADE #1 OF THE DAY R/R 2.6 : 1 • RQD 88 (A+)
$ANET Arista Networks Inc.
LONG (BUY SETUP)
1. Get In (Entry)
$164.14
2. Hard Stop
$154.80 (-5.7%)
3. Get Out (T1/T2)
$178.00 / $188.50
Entry Rule: Buy between $162.50 – $165.00 (or on 15-min candle reclaim above $165.40)
Stop Logic: Hard stop at $154.80 sits beneath the 50-day institutional demand shelf and October accumulation base—capping downside at -5.69% while targeting $178.00 to $188.50 (+14.84%).
4. Why Now: Microsoft (+6.68%) and Amazon (+6.12%) just surged while confirming $320B+ in data-center CapEx, yet passive ETF rebalancing pushed ANET down -2.79% to $164.14. Arista owns the 64.1% gross-margin 800G/1.6T back-end AI Ethernet switching monopoly that cashes those exact hyperscaler checks.
Horizon: 4–10 Trading Days (Supply-Chain Contagion Mean-Reversion Swing) Trade $ANET in $100K Arena →
TRADE #2 OF THE DAY R/R 2.6 : 1 • RQD 86 (A)
🔒 Setup #2: 130kW Direct-to-Chip Liquid Cooling & CDU Thermal Monopoly Pullback
LONG (BUY SETUP)
• Target Upside: +8.8% (T1) to +15.1% (T2)
• Max Downside Stop: -5.7% Hard Floor (2.6 : 1 R/R)
Order book sold out through 2027 on key VWAP support. Enter your email below for the ticker, buy trigger, and stop.
TRADE #3 OF THE DAY R/R 2.3 : 1 • RQD 85 (A)
🔒 Setup #3: 13.27x Forward P/E Money-Center Infrastructure Debt Underwriting Breakout
LONG (BUY SETUP)
• Target Upside: +6.2% (T1) to +10.5% (T2)
• Max Downside Stop: -4.5% Hard Floor (2.3 : 1 R/R)
Big-bank infrastructure lender breaking out with a -4.5% stop floor. Enter your email below for the entry zone and target.
Horizon: 5–12 Trading Days (Relative-Strength Financials Breakout)
⚡ See Setups #2 & #3 Right Now + Tomorrow's 3 Setups at 8:00 AM ET
Free impersonal market research. Educational levels only — past setups include losing stops and carry real risk of loss.
2. Guru Strategy Screeners, Formula Hub & Head-to-Head Battles
4. Editorial Investigations, FRED Macro & Interactive Tools
LIVE TAPE